221 related articles for article (PubMed ID: 31123830)
1. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
Cariello M; Piglionica M; Gadaleta RM; Moschetta A
Handb Exp Pharmacol; 2019; 256():73-93. PubMed ID: 31123830
[TBL] [Abstract][Full Text] [Related]
2. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
Piglionica M; Cariello M; Moschetta A
Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis.
Gadaleta RM; Scialpi N; Peres C; Cariello M; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
Sci Rep; 2018 Nov; 8(1):17210. PubMed ID: 30464200
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor.
Gadaleta RM; Garcia-Irigoyen O; Cariello M; Scialpi N; Peres C; Vetrano S; Fiorino G; Danese S; Ko B; Luo J; Porru E; Roda A; Sabbà C; Moschetta A
EBioMedicine; 2020 Apr; 54():102719. PubMed ID: 32259714
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
6. Roles of FGF19 in liver metabolism.
Kir S; Kliewer SA; Mangelsdorf DJ
Cold Spring Harb Symp Quant Biol; 2011; 76():139-44. PubMed ID: 21813638
[TBL] [Abstract][Full Text] [Related]
7. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
8. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.
Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK
Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.
Wunsch E; Milkiewicz M; Wasik U; Trottier J; Kempińska-Podhorodecka A; Elias E; Barbier O; Milkiewicz P
Sci Rep; 2015 Aug; 5():13462. PubMed ID: 26293907
[TBL] [Abstract][Full Text] [Related]
10. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
[TBL] [Abstract][Full Text] [Related]
11. Developmental regulation of the intestinal FGF19 system in domestic pigs.
Gavaldà-Navarro A; Pastor JJ; Mereu A; Villarroya F; Ipharraguerre IR
Am J Physiol Gastrointest Liver Physiol; 2018 Jun; 314(6):G647-G654. PubMed ID: 29446652
[TBL] [Abstract][Full Text] [Related]
12. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
Johansson H; Svensson JF; Almström M; Van Hul N; Rudling M; Angelin B; Nowak G; Fischler B; Ellis E
J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601
[TBL] [Abstract][Full Text] [Related]
13. A nontumorigenic variant of FGF19 treats cholestatic liver diseases.
Luo J; Ko B; Elliott M; Zhou M; Lindhout DA; Phung V; To C; Learned RM; Tian H; DePaoli AM; Ling L
Sci Transl Med; 2014 Jul; 6(247):247ra100. PubMed ID: 25080475
[TBL] [Abstract][Full Text] [Related]
14. Developmental regulation of the gut-liver (FGF19-CYP7A1) axis in neonates.
Memon N; Griffin IJ; Lee CW; Herdt A; Weinberger BI; Hegyi T; Carayannopoulos MO; Aleksunes LM; Guo GL
J Matern Fetal Neonatal Med; 2020 Mar; 33(6):987-992. PubMed ID: 30122083
[No Abstract] [Full Text] [Related]
15. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.
Wu X; Li Y
Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585
[TBL] [Abstract][Full Text] [Related]
16. Tissue-specific mechanisms of bile acid homeostasis and activation of FXR-FGF19 signaling in preterm and term neonatal pigs.
Vonderohe C; Guthrie G; Stoll B; Chacko S; Dawson H; Burrin DG
Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G117-G133. PubMed ID: 34851728
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A.
Jahn D; Sutor D; Dorbath D; Weiß J; Götze O; Schmitt J; Hermanns HM; Geier A
Biochim Biophys Acta; 2016 Feb; 1859(2):381-92. PubMed ID: 26723851
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
19. A gut-brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus.
Liu S; Marcelin G; Blouet C; Jeong JH; Jo YH; Schwartz GJ; Chua S
Mol Metab; 2018 Feb; 8():37-50. PubMed ID: 29290621
[TBL] [Abstract][Full Text] [Related]
20. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis.
Schaap FG; van der Gaag NA; Gouma DJ; Jansen PL
Hepatology; 2009 Apr; 49(4):1228-35. PubMed ID: 19185005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
